- Patent Number:
11779,577
- Appl. No:
17/175101
- Application Filed:
February 12, 2021
- نبذة مختصرة :
This application relates to methods of diagnosing and treating anorexia nervosa (AN) and binge eating disorder (BED) with a nonselective activator of metabotropic glutamate receptors (mGluRs).
- Inventors:
The Children's Hospital of Philadelphia (Philadelphia, PA, US)
- Assignees:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA (Philadelphia, PA, US)
- Claim:
1. A method of treating anorexia nervosa (AN) in a subject with attention deficit hyperactivity disorder (ADHD), the method comprising administering fasoracetam to the subject.
- Claim:
2. The method of claim 1 , wherein the fasoracetam is fasoracetam monohydrate.
- Claim:
3. The method of claim 1 , wherein the fasoracetam is administered at a dose of 50-400 mg and wherein the dose is administered once, twice, or three times daily.
- Claim:
4. The method of claim 1 , wherein the fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg, or 400 mg twice daily.
- Claim:
5. The method of claim 1 , wherein the subject has at least one genetic alteration in a metabotropic glutamate receptor (mGluR) network gene.
- Claim:
6. The method of claim 5 , wherein the genetic alteration is a copy number variation (CNV).
- Claim:
7. The method of claim 6 , wherein the CNV is a deletion.
- Claim:
8. The method of claim 6 , wherein the CNV is a duplication.
- Claim:
9. The method of claim 5 , wherein at least one of the following applies: (i) the genetic alteration is in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes; (ii) the genetic alteration is in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 2 mGluR network genes; or (iii) the genetic alteration is in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 3 mGluR network genes.
- Claim:
10. The method of claim 5 , wherein the genetic alteration is not in one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.
- Claim:
11. The method of claim 1 , wherein the subject has the bingeing and/or purging subtype of AN.
- Claim:
12. The method of claim 1 , wherein the subject has the restricting subtype of AN.
- Claim:
13. The method of claim 1 , wherein the subject is a pediatric or adolescent subject.
- Claim:
14. The method of claim 1 , wherein the subject is an adult subject.
- Claim:
15. The method of claim 1 , wherein the subject is already taking or is administered one or more of an antidepressant, an anxiolytic or an anti-psychotic.
- Claim:
16. The method of claim 15 , wherein the antidepressant is fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, a tricyclic antidepressant, a selective serotonin reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a norepinephrine and dopamine reuptake inhibitor, or a monoamine oxidase inhibitor.
- Claim:
17. The method of claim 15 , wherein the anxiolytic is a barbiturate, pregabalin, or a benzodiazepine.
- Claim:
18. The method of claim 15 , wherein the anti-psychotic is olanzapine, quetiapine, aripiprazole or risperidone.
- Claim:
19. The method of claim 1 , wherein the fasoracetam is administered in combination with non-pharmaceutical therapy selected from vagus nerve stimulation, repetitive transcranial magnetic stimulation, magnetic seizure therapy, and deep brain stimulation.
- Patent References Cited:
10918632 February 2021 Hakonarson
2006/048771 May 2006
2011/073347 June 2011
2015/032790 March 2015
- Other References:
Wang, K. et al., “A genome-wide association study on common SNPs and rare CNVs in anorexia nervosa”, Molecular Psychiatry, 16(9): 949-959 (2010). cited by applicant
Hinney, A. et al., “Evience for three genetic loci involved in both anorexia nervosa risk and variation of body mass index”, Molecular Psychiatry, 22(2): 192-201 (2016). cited by applicant
Boraska, V. et al., “A genome-wide association study of anorexia nervosa”. Molecular Psychiatry, 19(10): 1085-1094 (2014). cited by applicant
Shannon, P. et al., “Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks”, Genome Research, 13(11): 2498-2504 (2003). cited by applicant
Weiland, T.J. et al., “Metabotropic glutamate receptors mediate lipopolysaccharide-induced fever and sickness behavior”. Brain, Behavior and Immunity, Academic Press, San Diego, CA, US, vol. 20, No. 3: 233-245 (2006). cited by applicant
International Search Report, dated Feb. 5, 2018, issued in corresponding International Application No. PCT/US2017/050228. cited by applicant
Written Opinion, dated Feb. 5, 2018, issued in corresponding International Application No. PCT/US2017/050228. cited by applicant
Henrichsen, Charlotte et al., “Copy number variants, diseases and gene expression”, Human Molecular Genetics, 18: Review issue 1, doi:10.1093/hmg/ddp011 (2009). cited by applicant
Hirouchi, Masaaki et al., “Role of metabotropic glutamate receptor subclasses in modulation of adenylyl cyclase activity by a nootropic NS-105”, European Journal of Pharmacology, 387: 9-17 (2009). cited by applicant
Malykh, Andrei et al., “Piracetam and Piracetam-Like Drugs”, Drugs, 70(3): 287-312 (2010). cited by applicant
Oka, Michiko et al., “Involvement of metabotropic glutamate receptors in G1- and G8-dependent modulation of adenylate cyclase activity induced by a novel cognition enhancer NS-105 in rat brain”, Brain Research, 754: 121-130 (1997). cited by applicant
Wang, Kai et al., “Penn CNV: An integrated hidden Markov model designed for high-resolution copy No. variation detection in whole-genome SNP genotyping data”, Genome Research, 17: 1665-1674, Cold Spring Harbor Laboratory Press (2007). cited by applicant
- Primary Examiner:
Mauro, John M
- Attorney, Agent or Firm:
Rigaut, Kathleen D.
Howson & Howson LLP
- الرقم المعرف:
edspgr.11779577
Processing Request
No Comments.